-
-
-
-
-
-
-
Guardant Health partners with Nuvalent for cancer diagnostics development
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on Nuvalent (NUVL)
-
-
-
-
-
-
-
Nuvalent to present preclinical data for HER2 inhibitor at cancer conference
-
-
-
-
-
-
-
Nuvalent (NUVL) PT Raised to $114 at UBS
-
-
-
-
-
-
-
Nuvalent Inc (NUVL) Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones
-
-
-
-
-
-
-
Baird Reiterates Outperform Rating on Nuvalent (NUVL)
-
-
-
-
-
-
-
Nuvalent (NUVL) PT Raised to $115 at Stifel
-
66,735 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

